Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Subscribe To Our Newsletter & Stay Updated